This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Given the complexity of diagnosing rare disease patients, identifying real-world prevalence rates is difficult, as ranges from academic literature are often...
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...
Greg Bell is a panelist during the session titled “Navigating Life Sciences disputes. An arbitrator’s perspective.” For more information on this event, click...
CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as...
